FKF 02SC

Drug Profile

FKF 02SC

Alternative Names: FKF02SC; TGOF 02N

Latest Information Update: 08 Jan 2016

Price : $50

At a glance

  • Originator Unknown
  • Developer Fabre-Kramer Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor modulators; Histamine H1 receptor modulators; Serotonin 1A receptor modulators; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 08 Jan 2016 Phase II development for Schizophrenia is ongoing in USA
  • 08 Jan 2009 FKF 02SC is available for licensing (http://www.fabrekramer.com)
  • 08 Jan 2009 Phase-II clinical trials in Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top